Prescient Therapeutics (ASX: PTX) receives R&D Tax Rebate of $2.4M

November 28, 2023 12:01 AM EST | By Manisha
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp
 Prescient Therapeutics (ASX: PTX) receives R&D Tax Rebate of $2.4M
Image source: Pexels.com

Highlights

  • Prescient Therapeutics has received AU$2.4 million as R&D Tax Incentive rebate for FY23.
  • R&D Tax Incentive is given under a government program providing firms cash refunds of up to 43.5% of eligible R&D expenses.
  • PTX is engaged in developing targeted and cell therapies for cancer treatment.

In the latest announcement, clinical-stage oncology company Prescient Therapeutics Limited (ASX: PTX) revealed the receipt of AU$2.4 million as R&D Tax Incentive rebate for the financial year 2023. This amount received by PTX is in addition to the AU$18.7 million cash reserves posted in the last quarter ended 30 September 2023.

The R&D (research and development) Tax Incentive falls under a program run by the Australian Government providing firms cash refunds of up to 43.5% of eligible R&D expenses.

Also read: Encouraging outcomes from Prescient Therapeutics’ (ASX:PTX) clinical-stage assets light up last quarter

Share price performance
PTX shares have gained over 38% in the past one month. At the time of writing this article on 28 November 2023, the stock was spotted trading at AU$0.083, approximately 6.4% higher from the last closing price. The company has a market cap of over AU$54 million.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Incorporated (Kalkine Media), Business Number: 720744275BC0001 and is available for personal and non-commercial use only. The advice given by Kalkine Media through its Content is general information only and it does not take into account the user’s personal investment objectives, financial situation and specific needs. Users should make their own enquiries about any investment and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media is not registered as an investment adviser in Canada under either the provincial or territorial Securities Acts. Some of the Content on this website may be sponsored/non-sponsored, as applicable, however, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used in the Content unless stated otherwise. The images/music that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Canadian AI All-Stars: Unveiling the Top Stocks for 2024

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.